Bellevue Group Ag Xencor Inc Transaction History

Bellevue Group Ag

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$24.62 - $32.44 $27,082 - $35,684	-1,100 Reduced 4.15%	25,400 $660,000
Q2 2022 Aug 11, 2022	SELL	$19.74 - $29.01 $298,074 - $438,051	-15,100 Reduced 36.3%	26,500 $725,000
Q1 2022 May 13, 2022	SELL	$26.68 - $41.63 $280,140 - $437,115	-10,500 Reduced 20.15%	41,600 $1.11 Million
Q3 2021 Nov 12, 2021	SELL	$30.65 - $35.68 $30,650 - $35,680	-1,000 Reduced 1.88%	52,100 $1.7 Million
Q1 2021 May 12, 2021	BUY	$40.81 - $53.88 $734,580 - $969,840	18,000 Added 51.28%	53,100 $2.29 Million
Q4 2020 Feb 16, 2021	BUY	$36.63 - $47.63 $1.29 Million - $1.67 Million	35,100 New	35,100 $1.53 Million

214

71.8M

2.5K

7.9K

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.09B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.